Compare Quanta Services Inc (PWR) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quanta Services Inc vs Zimmer Biomet Holdings Inc — how do they compare? Quanta Services Inc trades at $705.94 (market cap $103.03B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Quanta Services Inc is far larger — about 6.1× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.08%). Which is the better fit depends on your goals — on Pluang, investors hold Quanta Services Inc for 62 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| PWR | ZBH | |
|---|---|---|
Market Cap | $103.03B | $16.95B |
Volume | 977,892 | 2,505,240 |
Sector | Industrials | Health |
52-Week High | $785.24 | $103.98 |
52-Week Low | $412.21 | $79.58 |
Typical Hold Time | 62 Days | 89 Days |
Enterprise Value | $109.13B | $24.02B |
Dividend Yield | 0.06% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PWR trades at $685.33, down 2.25% today but maintains strong technical momentum with bullish moving averages and support at $684. The company demonstrates robust fundamentals with revenue growth from $23.7B to $28.5B in 2025 and consistent earnings beats, while analyst sentiment remains overwhelmingly positive with 27 buy ratings and a $802.08 consensus target.
PWR offers compelling growth exposure to infrastructure and AI-driven data center demand, supported by a record $53B backlog and margin expansion potential. Key risks include execution challenges on large projects and sensitivity to economic cycles, but strong institutional support and positive earnings momentum suggest continued upside potential.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and maintains a solid gross profit margin of 69.87%. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated. Analyst consensus is a 'Buy' with a $103.11 price target, indicating potential upside from current levels.
The outlook for ZBH is cautiously optimistic, supported by earnings momentum and a diversified medical technology portfolio. Key risks include rising debt levels, with debt-to-asset ratio increasing to 32.57% in 2025, and competitive pressures in the healthcare sector. Institutional ownership trends show continued interest, but investors should monitor margin sustainability and capital expenditure efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
